UTI Healthcare (Equity, Equity Sectoral-pharma)

19 yrs 5 monthsStarted on:28 Jun 1999
₹ 441.05 Cras on: 13 Nov 2018
Long Term Horizon
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.

Exit Load

Scheme Documents

Similar Funds
Reliance Pharma
Current NAV 1114.25
Return (CAGR) 20.78%
Crisil Ranking NA
Value Research NA
SBI Healthcare Opportunities
Current NAV 1114.25
Return (CAGR) 15.36%
Crisil Ranking NA
Value Research NA


TenureReturns (CAGR)
1 YR0.84

SIP Returns

TenureReturns (CAGR)
5 YR0.88
10 YR11.06


Company Name% Assets
Sun Pharmaceutical Inds. Ltd.9.58
Cipla Ltd.8.57
Dr. Reddy's Laboratories Ltd.7.05
Cadila Healthcare Ltd.6.61
Ipca Laboratories Ltd.6.48
Torrent Pharmaceuticals Ltd.6.35
Divi's Laboratories Ltd.6.24
Sanofi India Ltd.6.18
Pfizer Ltd.4.7
Ajanta Pharma Ltd.4.52

Top Sectoral Holdings

Sector Name% Assets


Portfolio turnover ratio49
Standard Deviation16.43%

V Srivatsa

Mr. Srivatsa is a B.Com (H), Chartered Accountant, CWA. and PGDM from IIM Indore.
Prior to joining UTI in 2002 he has worked with Ford, Rhodes Parks & Co., Chartered Accountants and Madras Cements Ltd.

Other Funds Managed by V Srivatsa

  • Nav as on 13 Nov 18 33.18
    Returns since inception (CAGR) 12.76%
    Value Research
    Crisil Ranking NA
  • Nav as on 13 Nov 18 59.57
    Returns since inception (CAGR) 12.76%
    Value Research
    Crisil Ranking 2
© CRISIL Limited 2017. All Rights Reserved